Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a growing $22.8 billion therapeutics market. Read the IPO report here ...

Daddy had once been 6 feet tall and 155 pounds. Now at 5 foot 8 and just 123 pounds, he weighed less than anyone else in the ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

An international study has identified two types of these so-called dysbioses in cystic fibrosis. They display ... Landmark Study Involving Babies in Ireland Supports Use of Cystic Fibrosis Drug in ...

"Glox to develop precision antibiotics for cystic fibrosis" was originally created and published by Pharmaceutical Technology ...

Bryan Freedman, now defending his client against Blake Lively’s accusations over 'It Ends With Us,' claimed Baldoni’s ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Virtual choir program founder Ashley Ballou-Bonnema shares her selfless story on living with and advocating for a life with the chronic disease.

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses. Scientists believe key immune elements – cells and genes – may explain resolution ...